Daniel Joseph Apel sold $934k of ARWR
Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC.. 13,095 shares at an average of $71.35, traded Apr 22, 2026, filed Apr 24, 2026.
Score components
- +22RoleCFO
- +24Trade size$934k at market
- 0Share of holdings soldSold 7.4% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +1.4%, 3m +15.8%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000879407-26-000039, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | SOpen-market sale Common Stock10b5-1 | -3,208 | $70.11 | $225k | 172,792 | Apr 24, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stock10b5-1 | -1,157 | $70.45 | $82k | 171,635 | Apr 24, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stock10b5-1 | -8,730 | $71.92 | $628k | 162,905 | Apr 24, 2026 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $174k 2,000 shares | -6% | |
| 48Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Michael S Perry director | $1.0M 11,600 shares | -9% | |
| 8Weak | ARROWHEAD PHARMACEUTICALS, INC. | Hongbo Lu director | $228k 2,970 shares | -5% | |
| 25Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $750k 10,000 shares | -4% | |
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $2.5M 40,164 shares | -19% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% | |
| 28Weak | ARROWHEAD PHARMACEUTICALS, INC. | Mauro Ferrari director | $527k 7,530 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.